DK0648127T3 - Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis - Google Patents

Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis

Info

Publication number
DK0648127T3
DK0648127T3 DK92924432T DK92924432T DK0648127T3 DK 0648127 T3 DK0648127 T3 DK 0648127T3 DK 92924432 T DK92924432 T DK 92924432T DK 92924432 T DK92924432 T DK 92924432T DK 0648127 T3 DK0648127 T3 DK 0648127T3
Authority
DK
Denmark
Prior art keywords
type
epidermidis
surface antigens
staphylococcus epidermidis
serotypes
Prior art date
Application number
DK92924432T
Other languages
English (en)
Inventor
Ali Ibrahim Fattom
D Craig Wright
Walter W Karakawa
Original Assignee
Univax Biolog Inc
Ali Ibrahim Fattom
D Craig Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Biolog Inc, Ali Ibrahim Fattom, D Craig Wright filed Critical Univax Biolog Inc
Application granted granted Critical
Publication of DK0648127T3 publication Critical patent/DK0648127T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK92924432T 1991-11-22 1992-11-20 Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis DK0648127T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79625291A 1991-11-22 1991-11-22
PCT/US1992/009784 WO1993009811A1 (en) 1991-11-22 1992-11-20 TYPE I AND TYPE II SURFACE ANTIGENS ASSOCIATED WITH $i(STAPHYLOCOCCUS EPIDERMIDIS)

Publications (1)

Publication Number Publication Date
DK0648127T3 true DK0648127T3 (da) 2003-05-19

Family

ID=25167715

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92924432T DK0648127T3 (da) 1991-11-22 1992-11-20 Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis

Country Status (12)

Country Link
US (2) US5866140A (da)
EP (1) EP0648127B1 (da)
JP (2) JP4087896B2 (da)
AT (1) ATE237351T1 (da)
AU (1) AU681573B2 (da)
CA (1) CA2123811C (da)
DE (1) DE69233012T2 (da)
DK (1) DK0648127T3 (da)
ES (1) ES2198405T3 (da)
FI (1) FI111336B (da)
NO (1) NO319013B1 (da)
WO (1) WO1993009811A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
JP4160633B2 (ja) * 1994-09-21 2008-10-01 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CA2341177A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
ATE421883T1 (de) * 1998-09-14 2009-02-15 Nabi Biopharmaceuticals Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
SI1745075T1 (sl) 2004-04-21 2013-07-31 The Brigham And Women's Hospital, Inc. Poli-N-acetilglukozamin (PNAG/dPNAG) vezavni peptidi in postopki za njihovo uporabo
ES2540770T3 (es) * 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
CN101175508A (zh) 2004-10-21 2008-05-07 惠氏公司 表皮葡萄球菌多肽抗原的免疫原性组合物
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
WO2006076058A1 (en) * 2005-01-10 2006-07-20 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
AR055580A1 (es) 2005-06-13 2007-08-29 Nabi Biopharmaceuticals Uso de leucocidina de panton valentine para el tratamiento y prevencion de infecciones por estafilococos
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
US7754225B2 (en) * 2006-07-20 2010-07-13 Glaxosmithkline Biologicals S.A. Method of protecting against staphylococcal infection
AU2008280799B2 (en) * 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
BR122019005883A8 (pt) * 2009-10-30 2022-10-04 Novartis Ag Método para liberação de polissacarídeo capsular, processo de purificação de sacarídeos capsulares tipo 5 e tipo 8 de staphylococcus aureus e composição
RU2589256C2 (ru) 2010-12-03 2016-07-10 Санофи Пастер Лимитид Композиции и способы для иммунизации против streptococcus pneumoniae
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5055455A (en) * 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens

Also Published As

Publication number Publication date
ATE237351T1 (de) 2003-05-15
US5961975A (en) 1999-10-05
JP4087896B2 (ja) 2008-05-21
NO941877D0 (no) 1994-05-19
CA2123811A1 (en) 1993-05-27
DE69233012T2 (de) 2003-11-06
AU3074792A (en) 1993-06-15
AU681573B2 (en) 1997-09-04
JP2004155789A (ja) 2004-06-03
FI111336B (fi) 2003-07-15
FI942359A0 (fi) 1994-05-20
EP0648127A1 (en) 1995-04-19
CA2123811C (en) 2005-07-05
FI942359A (fi) 1994-05-20
ES2198405T3 (es) 2004-02-01
NO941877L (no) 1994-06-16
US5866140A (en) 1999-02-02
NO319013B1 (no) 2005-06-06
JP4353789B2 (ja) 2009-10-28
EP0648127A4 (en) 1995-06-14
DE69233012D1 (de) 2003-05-22
WO1993009811A1 (en) 1993-05-27
EP0648127B1 (en) 2003-04-16
JPH07508498A (ja) 1995-09-21

Similar Documents

Publication Publication Date Title
DK0648127T3 (da) Type I- og type II-overfladeantigener associeret med Staphylococcus epidermidis
LV10203A (lv) Panemiens inficesanas ar AIDS noteiksanai olbaltumvielu kompozicija test-komplekts
ATE188708T1 (de) Antikörperderivate
ATE70309T1 (de) Menschliche monoklonale antikoerper gegen bakterielle toxine.
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
ATE7761T1 (de) Impfstoff und herstellungsverfahren.
DK98187D0 (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
ATE45961T1 (de) Humanes cytomegalovirus immunserumglobulin mit hohem titer und verfahren zu seiner herstellung.
EP0041897A3 (en) Polysaccharide antigen from streptococcus and vaccine containing the same
SE9000333D0 (sv) Monoklonal antikropp
AU2456888A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
YU22693A (sh) Rekombinantna humana monoklonalna antitela koja neutrališu hiv, za sprečavanje i tretiranje hiv infekcije
DE69109314D1 (de) Humaner monoklonaler Antikörper und diesen enthaltende Arzneimittelzusammensetzung zur Behandlung von Pseudomonasinfektionen.
DE69025629T2 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids-verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
EP0327648A4 (en) HUMAN MONOCLONAL ANTIBODIES AND MEDICINES FOR PROPHYLAXIS AND TREATMENT OF INFECTIOUS DISEASES.
ATE207119T1 (de) Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind
DE3381985D1 (de) Verwendung von peptiden.
ATE110786T1 (de) Monoklonaler antikörper gegen exotoxin a von pseudomonas aeruginosa.
DE68924963T2 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome
SU1565021A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus - продуцент моноклональных антител к вирусу ящура 0-01618
UA37623A (uk) Спосіб одержання сироватки проти стрептококових та стафілококових інфекцій у тварин